German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding will support commercialization of the company’s Twinhale digital twin lung simulation software, which provides patient-specific drug deposition modeling for in silico trials of inhaled drugs.
Ebenbuild says that it has conducted pilot studies of the software in partnership with PARI Pharma and Pieris Pharmaceuticals and that a validation study of the Twinhale platform demonstrated “unprecedented accuracy.”
Ebenbuild CEO Kei Müller commented, “Our vision is to become the leading health intelligence platform for respiratory diseases. Twinhale is just the beginning. The very same core platform will power future regulated products for mechanical ventilation optimization and chronic respiratory disease management.”
Ebenbuild Head of In Silico Trials Maximilian Grill said, “With Twinhale, we are not only reducing attrition rates in respiratory drug development, we are also generating first-of-its-kind datasets that can drive regulatory acceptance and unlock companion diagnostic strategies in the future.”
Read the Ebenbuild press release
